Clinical Trial

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

Study acronym: NEXICART-3
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Trial Details
NCT Number NCT07709715
Lead Sponsor Nexcella Inc.
Collaborators: Immix Biopharma, Inc.
Conditions Light Chain (AL) Amyloidosis
Enrollment 260 participants
Start Date 2027-01
Primary Completion 2028-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16